Our results show that suppressing FXR signalling with the clinically approved drug UDCA—which is used as a first-line treatment in primary biliary cholangitis (PBC)26—or with the over-the-counter drug ZGG reduces the expression of ACE2 in multiple cell types. This evidence concerns the gene ACE2 and primary biliary cholangitis.